drugset / Trial / NCT01889420

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01889420

NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to test the possibility that a combination of three drugs, pomalidomide and everolimus with dexamethasone, may improve patient responses when compared with use of either drug alone, with dexamethasone in refractory/relapsed multiple myeloma.

Timeline

Start
2014-07
Primary completion
2015-06
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral
Subject Everolimus Small molecule Oral
Subject Pomalidomide Other / unclassified Oral

Indications